Details for New Drug Application (NDA): 021743
✉ Email this page to a colleague
The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.
Summary for 021743
| Tradename: | TARCEVA |
| Applicant: | Osi Pharms |
| Ingredient: | erlotinib hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 021743
| Mechanism of Action | Protein Kinase Inhibitors |
Medical Subject Heading (MeSH) Categories for 021743
Suppliers and Packaging for NDA: 021743
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743 | NDA | Genentech, Inc. | 50242-062 | 50242-062-01 | 30 TABLET in 1 BOTTLE (50242-062-01) |
| TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743 | NDA | Genentech, Inc. | 50242-063 | 50242-063-01 | 30 TABLET in 1 BOTTLE (50242-063-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 18, 2004 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 18, 2004 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 18, 2004 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 021743
Complete Access Available with Subscription
